CLL-224 Coronavirus Disease Mortality and Outcome in Macedonian Patients With Chronic Lymphocytic Leukemia: Single-Center Experience

• Published in: Clinical lymphoma, myeloma and leukemia Vol. 22; p. S274
• Main Authors: Trajkova, Sanja, Veljanovska, Aleksandra Pivkova, Labacevska, Marija Popova, Ridova, Nevenka, Stojanovska, Simona, Dukovski, Dushko, Stavridis, Irina Panovska
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 01-10-2022
• Subjects: Acute Lymphoblastic Leukemia
• ISSN: 2152-2650; 2152-2669
• DOI: 10.1016/S2152-2650(22)01337-4

Context:
Patients with chronic lymphocytic leukemia (CLL) may be more predisposed to coronavirus disease 2019 (COVID-19) due to age, the nature of the disease, and treatment-related immunosuppression.
Objective:
The aim of the study was to assess risk factors of the outcome and course of COVID-19 for CLL patients in Macedonia.
Design:
Retrospective study of patients with CLL and COVID-19 infection in the period of time from the beginning of the pandemic to March 2022.
Setting:
Individual patient data from 55 CLL patients with COVID-19 infection were analyzed. The risk factors of COVID-19 disease severity and outcomes were investigated.
Interventions:
The outcome was the analysis of patients with COVID-19 infection in line with host risk factors and biological heterogeneity of the disease with previous therapy for CLL.
Results:
Our evaluation has shown that 80% of patients were male and 20% were female. The average age was 65 years. The average CIRS score was 2 and BMI was 23.6. Most of the patients (67.2%) have unmutated Ig genes. Ninety-one percent (91%) from that subgroup of patients have a severe form of COVID-19, 82% of patients were treated with chemotherapy, and 48% had a fatal outcome.
Conclusions:
CLL-directed treatment and unmutated Ig genes were significant risk factors for survival. Untreated patients and patients with mutated IGHV had a better chance of survival than those on treatment or who were recently treated.